Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 417,824 shares at $13.14 ($5.5M) on 2025-08-01, disclosed to the SEC on 2025-08-05.
Scheduled sale ($5.5M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.14 | 208,912 | $2.7M | 50.0% |
| 2 | $13.14 | 208,912 | $2.7M | 50.0% |
| Total | $13.14 avg | 417,824 | $5.5M | 100% |
| Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |
| VRNA | SELL | 2024-12-06 | $8.5M | — | Filing → |